triflusal has been researched along with Allergy, Drug in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fuertes Ferre, G; Galache Osuna, JG; Laita Monreal, S; Ortas Nadal, MDR; Sánchez Insa, E; Sánchez Rubio-Lezcano, J | 1 |
Blasco, A; Del Pozo, MD; Escudero, R; Gonzalez, I; Lobera, T; Sánchez, M | 1 |
Colás, C; Cubero, JL; Millán, P; Simó Sánchez, B | 1 |
Borja, J; Fraj, J; Izquierdo, I; Pérez, I; Picado, C; Valero, A; Vives, R | 1 |
1 trial(s) available for triflusal and Allergy, Drug
Article | Year |
---|---|
Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Probability; Reference Values; Respiratory Function Tests; Risk Assessment; Salicylates; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2008 |
3 other study(ies) available for triflusal and Allergy, Drug
Article | Year |
---|---|
Triflusal in Patients With Aspirin Hypersensitivity Treated With Coronary Stent Implantation.
Topics: Aged; Aspirin; Drug Hypersensitivity; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Salicylates; Stents | 2018 |
Tolerance of triflusal in patients with immediate cutaneous hypersensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Platelet Aggregation Inhibitors; Salicylates; Skin Diseases | 2014 |
Aspirin desensitization in patients with coronary artery disease: Cost savings.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensitivity; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Salicylates; Ticlopidine | 2017 |